Ambrx Biopharma(AMAM.US)

Last Updated 19:00:00 ET
longbridge loading

04:17 ETFapon Biopharma Presents at AACR Annual Meeting 2026, Showcasing Core Technology Platforms and Advancing Pipeline

prnewswire·
US
AMAM
0.00%
US
PBE
+0.35%
US
BIB
+1.41%
prnewswire·
US
AMAM
0.00%
US
PBE
+0.35%
US
BIB
+1.41%

Lytix Biopharma Grants Share Options to Board Member Under Incentive Plan

Tip Ranks·
US
IBBQ
+0.82%
US
XBI
+0.81%
US
IXJ
+0.67%
Tip Ranks·
US
IBBQ
+0.82%
US
XBI
+0.81%
US
IXJ
+0.67%

Argent BioPharma Shareholders Back Capital Moves at General Meeting

Tip Ranks·
US
XLV
+0.69%
US
AMAM
0.00%
US
LABU
+2.48%
Tip Ranks·
US
XLV
+0.69%
US
AMAM
0.00%
US
LABU
+2.48%

Bora Biologics Successfully Completes 2,000L Engineering and Scale-Up Run in San Diego, Reinforcing Commercial-Scale Readiness

MorningStar·
US
TBPH
-1.27%
US
IXJ
+0.67%
US
BBH
+0.64%
MorningStar·
US
TBPH
-1.27%
US
IXJ
+0.67%
US
BBH
+0.64%

Xbrane Sets April–May Target to Resubmit Ranibizumab Biosimilar BLA to U.S. FDA

Tip Ranks·
US
XBIO
+3.70%
US
BBH
+0.64%
US
PBE
+0.35%
Tip Ranks·
US
XBIO
+3.70%
US
BBH
+0.64%
US
PBE
+0.35%

Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient | CANF Stock News

StockTitan·
US
CANF
-0.58%
StockTitan·
US
CANF
-0.58%

Lytix Biopharma Calls April AGM and Proposes No 2025 Dividend

Tip Ranks·
US
LIXT
+5.54%
US
LSBCF
+35.14%
US
AMAM
0.00%
Tip Ranks·
US
LIXT
+5.54%
US
LSBCF
+35.14%
US
AMAM
0.00%

Lytix Biopharma Marks Pivotal 2025 With Strong Melanoma Data and Capital Raise

Tip Ranks·
US
IXJ
+0.67%
US
VHT
+0.64%
US
BBH
+0.64%
Tip Ranks·
US
IXJ
+0.67%
US
VHT
+0.64%
US
BBH
+0.64%
© 2026 Longbridge｜Disclaimer